Drug intelligence / Profile preview

RTR890

Development stage: Preclinical
Lead developer: Retro Biosciences
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

RTR890 is an induced pluripotent stem cell (iPSC)-derived hematopoietic stem cell (HSC) therapy being developed by Retro Biosciences. The program utilizes cellular reprogramming technology to generate functional hematopoietic stem cells intended for the treatment of various blood disorders. By providing a source of healthy, lab-grown HSCs, the therapy aims to replace or augment a patient's existing hematopoietic system, potentially addressing conditions that currently require bone marrow or stem cell transplants. RTR890 is part of a broader pipeline focused on longevity and the reversal of age-related cellular decline, and it is currently in the preclinical stage of development.

Beyond the preview

Go deeper on RTR890.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RTR890.

Explore the full profile